Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Steven M. SNYDER |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Commentary: Objective aids for the assessment of ADHD – further clarification of what FDA approval for marketing means and why NEBA might help clinicians. A response to Arns et al. (2016) / Mark A. STEIN in Journal of Child Psychology and Psychiatry, 57-6 (June 2016)
[article]
Titre : Commentary: Objective aids for the assessment of ADHD – further clarification of what FDA approval for marketing means and why NEBA might help clinicians. A response to Arns et al. (2016) Type de document : Texte imprimé et/ou numérique Auteurs : Mark A. STEIN, Auteur ; Steven M. SNYDER, Auteur ; Thomas A. RUGINO, Auteur ; Mady HORNIG, Auteur Article en page(s) : p.770-771 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Neuropsychiatric EEG-Based ADHD Assessment Aid (NEBA) is an EEG-based device designed to aid in the diagnostic process for ADHD by identifying individuals less likely to have ADHD by virtue of a lower theta/beta ratio. In using NEBA as an example, the Arns et al. commentary misstates the purpose of NEBA, which is to widen the differential rather than to make the diagnosis. Arns et al. caution about missing an ADHD diagnosis, but fail to mention the impact of overdiagnosis. If we are to advance our knowledge of the etiology and pathophysiology of ADHD, as well as develop tailored treatments and ultimately improve outcomes for ADHD, then biomarkers and objective assessment aids such as NEBA are needed to improve and refine diagnostic accuracy beyond symptom description and clinical history. En ligne : http://dx.doi.org/10.1111/jcpp.12534 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=289
in Journal of Child Psychology and Psychiatry > 57-6 (June 2016) . - p.770-771[article] Commentary: Objective aids for the assessment of ADHD – further clarification of what FDA approval for marketing means and why NEBA might help clinicians. A response to Arns et al. (2016) [Texte imprimé et/ou numérique] / Mark A. STEIN, Auteur ; Steven M. SNYDER, Auteur ; Thomas A. RUGINO, Auteur ; Mady HORNIG, Auteur . - p.770-771.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 57-6 (June 2016) . - p.770-771
Index. décimale : PER Périodiques Résumé : Neuropsychiatric EEG-Based ADHD Assessment Aid (NEBA) is an EEG-based device designed to aid in the diagnostic process for ADHD by identifying individuals less likely to have ADHD by virtue of a lower theta/beta ratio. In using NEBA as an example, the Arns et al. commentary misstates the purpose of NEBA, which is to widen the differential rather than to make the diagnosis. Arns et al. caution about missing an ADHD diagnosis, but fail to mention the impact of overdiagnosis. If we are to advance our knowledge of the etiology and pathophysiology of ADHD, as well as develop tailored treatments and ultimately improve outcomes for ADHD, then biomarkers and objective assessment aids such as NEBA are needed to improve and refine diagnostic accuracy beyond symptom description and clinical history. En ligne : http://dx.doi.org/10.1111/jcpp.12534 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=289